Conestoga Capital Advisors’s Myriad Genetics MYGN Stock Holding History

Conestoga Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-6,939	Closed	-$212K	–	118
2016 Q2	$212K	Sell	6,939 -400	-5%	-$13.9K	0.02%	110
2016 Q1	$275K	Sell	7,339 -3,565	-33%	-$134K	0.02%	91
2015 Q4	$471K	Sell	10,904 -1,546	-12%	-$65.3K	0.04%	69
2015 Q3	$467K	Hold	12,450	–	–	0.04%	66
2015 Q2	$423K	Buy	12,450 +156	+1%	+$5.3K	0.03%	74
2015 Q1	$435K	Sell	12,294 -156	-1%	-$5.58K	0.03%	76
2014 Q4	$424K	Hold	12,450	–	–	0.03%	81
2014 Q3	$480K	Sell	12,450 -3,600	-22%	-$134K	0.04%	63
2014 Q2	$625K	Hold	16,050	–	–	0.04%	56
2014 Q1	$549K	Sell	16,050 -3,030	-16%	-$93.9K	0.03%	72
2013 Q4	$400K	Buy	19,080 +1,900	+11%	+$48.1K	0.03%	85
2013 Q3	$404K	Sell	17,180 -550	-3%	-$15.6K	0.03%	77
2013 Q2	$476K	Buy	+17,730	New	+$514K	0.05%	65

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Conestoga Capital Advisors's MYGN Position: Q3 2016 in Review

Conestoga Capital Advisors sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 6,939 shares — an estimated $212K sold.

Conestoga Capital Advisors first reported a position in MYGN in Q2 2013 and held it in 13 quarters. The position peaked at $625K in Q2 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Conestoga Capital Advisors reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Conestoga Capital Advisors sold 6,939 Myriad Genetics shares in Q3 2016, an estimated $212K.
Conestoga Capital Advisors first reported a position in Myriad Genetics in Q2 2013 and held it in 13 quarters.
Conestoga Capital Advisors's Myriad Genetics position peaked at $625K in Q2 2014.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Conestoga Capital Advisors's 13F filing for Q3 2016, filed 11 Oct 2016.